author-photo

Nathalie A. Johnson

Jewish General Hospital
McGill University
University of British Columbia

165

Papers

8222

Citations

Citation Trend

Filter By

Papers (165) Sort By

Journal Conference Others

Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma.

2021
Show All
- Source
- Cite
- Save
Citations (0)
Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes.

2021 Journal of Surgical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Common clonal origin of chronic myelomonocytic leukemia and B cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant.

2021
Show All
- Source
- Cite
- Save
Citations (0)
A PHASE II STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP CHEMOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (1)
HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (1)
A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)